Steven Engle

Steven Engle joined Gradalis as Chief Executive Officer in April 2022. Before joining Gradalis, Mr. Engle served as CEO of CohBar, a clinical-stage mitochondria-based therapeutics developer, and CEO and Chair of XOMA, an antibody therapeutics company that helped develop products with multiple pharmaceutical companies including Novartis, Merck, Pfizer, and Takeda. Prior to XOMA, Mr. Engle served as CEO and Chair of La Jolla Pharmaceutical Company, which was the first to discover the biology of B cell tolerance, developed the first B cell toleragen for lupus patients and received an approvable letter from the FDA. While at drug delivery systems company Cygnus, he helped gain FDA approval of and launch Nicotrol for smoking cessation. Steve is a former board member of BIO, Biocom and Baybio. Mr. Engle received his B.S. in Electrical Engineering, with a focus in biomedical engineering, and an M.S. in Electrical Engineering from the University of Texas Austin.